MERZ-THERAPEUTICS
11.8.2021 10:02:13 CEST | Business Wire | Press release
wMerz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced today that they have entered into a strategic license and collaboration agreement for the delivery of botulinum neurotoxin A (Xeomin®) ) to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder and interstitial cystitis and other urology indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210811005052/en/
Stefan Brinkmann, CEO Merz Therapeutics: “This strategic, long-term partnership with the Israeli Start-up Vensica allows us to expand into the attractive market of overactive bladder. It perfectly reflects the potential and capabilities of our neurotoxin platform for the development of sizeable non-movement disorder indications, pursuing our promise to create better outcomes for more patients. We strongly believe in the innovative and less invasive treatment of bladder diseases using Vensica’s ultrasound-assisted delivery catheter and are therefore looking forward to bringing this new treatment option to the patients together with our partner Vensica.”
Vensica CEO, Avner Geva commented, “We are very excited about our strategic partnership with Merz. By licensing Merz’s Botulinum Toxin A, Xeomin® , we’ve achieved an important milestone in our journey to changing the lives of urological patients. We hope that together with Merz, we will be able to provide, needle-less and minimal invasive procedures to over 85 million patients around the world, enabling them to benefit from a minimal discomfort, anesthesia-free, outpatient experience. The partnership with Merz, which includes not only exclusive licensing of Xeomin® , but also development support, enables us to accelerate our clinical trials and regulatory process. We are thrilled Merz realized the potential and need and chose to invest in innovative medical technologies that can benefit patients worldwide.”
“The collaboration with Vensica is a great example for our Merz Corporate Venture Capital Initiative,” states Jörg Bergler, COO Merz Group. “Here, we are investing globally in companies who are pursuing innovative, breakthrough science. As an experienced partner, we are not only granting Vensica access to our toxin but also offer know-how and experience for the development and preparation of the regulatory approval process in an advisory capacity."
The long-term partnership includes Merz’s intention to participate and invest in Vensica. Under the terms of the agreement, Merz already received, in addition to royalties, equity shares from Vensica with the option for further investment in the upcoming years and will be represented with a seat in the Board of Directors. Vensica will be responsible for the pre-clinical and clinical development of the needleless device and will prepare and file the marketing approval application. Upon the marketing approval, Merz will be responsible for the manufacturing and supply of Xeomin® (incobotulinumtoxinA) and Vensica will manage commercial activities worldwide, except of Japan.
Vensica’s proprietary ultrasound-assisted drug delivery system is an innovative minimally invasive solution to urology. The system enables needleless delivery of drugs to the bladder wall in a simple and quick procedure. The platform drives treatment from the surgical center to the private clinics, as it removes the need for a highly trained urologist, staff, and anesthesia. The unique delivery profile enables uniform delivery of the neurotoxin to greater area of the bladder wall, which may increase its efficacy, such as earlier onset and longer effect. The device is at clinical development stage by Vensica Therapeutics an Israeli based company.
Xeomin® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm or hypersalivation. Merz uses state-of-the-art technology in its dedicated facility in Dessau, Germany, meeting the highest international standards for biologic manufacturing. The highly purified neurotoxin, the only active ingredient in Xeomin® , is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA. The lack of complexing proteins enables Xeomin® to reduce the production of neutralizing antibodies capable of lowering efficacy.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that meet patient and customer needs.
About Vensica Therapeutics Ltd.
Vensica is a urology therapeutics company based out of Israel. The company is developing a unique platform for drug delivery for several urinary bladder indications, based on a proprietary ultrasound-assisted drug delivery system. The company was founded in 2015 by Avner Geva, (Yale, B.Sc, Technion, M.Sc) and is led and backed by medical and therapeutic’s leaders, including chairman M.D., Ph.D, Nissim Darvish, Lew Pell, Laborie and The Trendlines Group.
About Merz
Merz Group is a global, diversified company based in Frankfurt, Germany, with the three businesses Merz Aesthetics, Merz Therapeutics and Merz Consumer Care. The company is family-owned for over 112 years and is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. In fiscal year 2019/20 (June 30), Merz generated revenue of EUR 981.5 million. The company employs 3,212 people in 28 countries worldwide. To learn more, please visit www.merz.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005052/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Liberis and Qred Complete Merger Following Regulatory Approval to Create Global SMB Financial Platform2.11.2026 09:00:00 CET | Press release
Key points The merger is complete following regulatory approval. The combined group serves more than 60,000 small businesses across 17 countries, with access to approximately 11.5 million addressable merchants. Emil Sunvisson becomes Group CEO and Rob Fairfield becomes Deputy CEO. Both brands, products, partner integrations and customer relationships continue as they do today. Liberis, a leading global embedded finance platform, and Qred, one of Europe’s foremost digital small business banks, today announced the completion of their merger, first announced in June 2026, following approval from the Swedish Financial Supervisory Authority (SFSA). The merger combines Qred’s regulated banking capability and direct relationships with small businesses with Liberis’s embedded finance technology and distribution through more than 30 partners, including Deliveroo, Vagaro and Nexi. The group serves more than 60,000 small businesses across 17 countries and has access to approximately 11.5 million
Car Connectivity Consortium Expands Focus on Digital Access for Two-Wheelers and Micromobility2.11.2026 09:00:00 CET | Press release
Ahead of EICMA 2026, CCC highlights industry collaboration around secure, interoperable digital access for motorcycles, scooters, and other two-wheeled vehicles The Car Connectivity Consortium® (CCC), the global organization advancing interoperable connectivity between vehicles and devices, today highlighted its expanding work across the two-wheeler and micromobility markets ahead of EICMA 2026 in Milan, Italy. Through its Light Motor & Mobility Task Group (LMTG), CCC is bringing member companies together to address the distinct digital access needs of these markets and identify opportunities to advance standardization and interoperability. Key highlights of CCC's two-wheeler and micromobility work include: Addressing two-wheeler digital access needs: LMTG is examining requirements across motorcycles, scooters, e-bikes and other two- and three-wheeled vehicles. Exploring new applications for digital key technology: Member discussions include vehicle access and starting, access to vehic
OpenGate Capital Completes the Acquisition of Maersk Training, the Global Safety Training and Gas Safety Services Business of Maersk2.11.2026 09:00:00 CET | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has completed the acquisition of Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Terms of the acquisition were not disclosed. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services and training. Through Maersk H2S Safety Services, the company provides specialized outsourced hydrogen sulphide and Health, Safety and Environment safety services for customers in high-risk operating environments. The H2S Safety Services team provides onsite supervision, monitoring and safety equipment maintenance where the safety of personnel and the protection of assets are critical. Through its training business, the company also delivers safety training, competency developmen
SES to Supply Finnair with Ground-like Connectivity Experience in the Skies2.11.2026 08:00:00 CET | Press release
Multi-orbit inflight connectivity service will deliver faster, more reliable onboard internet experience to 18 Embraer aircraft SES today announced a new agreement with Finnair, Finland's flagship airline, to equip 18 E195-E2s with multi-orbit in-flight connectivity, enabling Finnair’s customers to enjoy fast, reliable internet access throughout their journey. Under the agreement, the Embraer E2 aircraft, which will be line-fitted at Embraer, will be equipped with SES’s electronically steered array antenna (ESA) offering reliable connectivity to the SES multi-orbit network, combining SES’s geostationary (GEO) satellite services with low-earth orbit (LEO) capacity from its partner Eutelsat. The first connected aircraft is expected to enter service in 2027. “Inflight Wi-Fi is a core part of the travel experience,” said Blane Boynton, Senior Vice President Aviation at SES. “SES’s multi-orbit network delivers the reliability, performance and flexibility airlines need today while providing
Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy2.11.2026 08:00:00 CET | Press release
Physician-investor and co-builder of Sofinnova's AI platform Sofia joins the partnership, underscoring the firm’s growing interest in healthtech and techbio Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, today announced the promotion of Javier Nunez-Vicandi to Partner. He joins Edward Kliphuis and Simon Turner in the firm’s Digital Medicine strategy, which invests in startups working at the intersection of biology, data, and AI. Since joining Sofinnova in 2022, Nunez-Vicandi has played a key role in the development of the firm's Digital Medicine strategy and broader AI efforts. He helped shape key AI investment theses within the Digital Medicine Strategy and is an observer on the boards of Latent Labs, Bioptimus, Cure51, Deepc, and Kiro. Javier has also recently led an investment that remains in stealth. Within Sofinnova's broader AI efforts, Javier co-led the project that created Sofia, Sofinnova's proprie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom